Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Distinct mutational pattern of T-cell large granular lymphocyte leukemia combined with pure red cell aplasia: Low mutational burden of STAT3

View through CrossRef
Abstract T-cell large granular lymphocyte leukemia (T-LGL) is often accompanied by pure red cell aplasia (PRCA). A high depth of next generation sequencing (NGS) was used for detection of the mutational profiles in T-LGL alone (n = 25) and T-LGL combined with PRCA (n = 16). Beside STAT3 mutation (41.5%), the frequently mutated genes included KMT2D (17.1%), TERT (12.2%), SUZ12 (9.8%), BCOR (7.3%), DNMT3A (7.3%), and RUNX1 (7.3%). Mutations of the TERT promoter showed a good response to treatment. Concomitant myelodysplastic syndrome (MDS) was detected in 7.3%. T-LGL combined with PRCA showed unique features (low VAF level of STAT3 mutation, low lymphocyte count, old age). Low ANC was detected in a STAT3 mutant with a low level of VAF, suggesting that even the low mutational burden of STAT3 is sufficient for reduction of ANC. In retrospective analysis of 591 patients without T-LGL, one MDS patient with STAT3 mutation was revealed to have subclinical T-LGL. T-LGL combined with PRCA may be classified as unique subtype of T-LGL. High depth NGS can enable sensitive detection of concomitant MDS in T-LGL. Mutation of the TERT promoter may indicate good response to treatment of T-LGL, thus, its addition to an NGS panel may be recommended.
Title: Distinct mutational pattern of T-cell large granular lymphocyte leukemia combined with pure red cell aplasia: Low mutational burden of STAT3
Description:
Abstract T-cell large granular lymphocyte leukemia (T-LGL) is often accompanied by pure red cell aplasia (PRCA).
A high depth of next generation sequencing (NGS) was used for detection of the mutational profiles in T-LGL alone (n = 25) and T-LGL combined with PRCA (n = 16).
Beside STAT3 mutation (41.
5%), the frequently mutated genes included KMT2D (17.
1%), TERT (12.
2%), SUZ12 (9.
8%), BCOR (7.
3%), DNMT3A (7.
3%), and RUNX1 (7.
3%).
Mutations of the TERT promoter showed a good response to treatment.
Concomitant myelodysplastic syndrome (MDS) was detected in 7.
3%.
T-LGL combined with PRCA showed unique features (low VAF level of STAT3 mutation, low lymphocyte count, old age).
Low ANC was detected in a STAT3 mutant with a low level of VAF, suggesting that even the low mutational burden of STAT3 is sufficient for reduction of ANC.
In retrospective analysis of 591 patients without T-LGL, one MDS patient with STAT3 mutation was revealed to have subclinical T-LGL.
T-LGL combined with PRCA may be classified as unique subtype of T-LGL.
High depth NGS can enable sensitive detection of concomitant MDS in T-LGL.
Mutation of the TERT promoter may indicate good response to treatment of T-LGL, thus, its addition to an NGS panel may be recommended.

Related Results

STAT3 Mutations in Large Granular Lymphocytic Leukemia
STAT3 Mutations in Large Granular Lymphocytic Leukemia
Abstract Abstract 1606 Introduction: Large granular lymphocytic leukemia (LGL leukemia) is a rare lymphoprolifera...
Abstract 1404: Novel STAT3 inhibitors targeting the STAT3 dimerization
Abstract 1404: Novel STAT3 inhibitors targeting the STAT3 dimerization
Abstract Background The STAT3 pathway may drive prostate cancer (PCa) progression to metastatic castration-resistant prostate cancer (mCRPC). STAT3 may serve as a go...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Abstract 1705: 3D growth modulates the competition between STAT3 and STAT5 in breast cancer
Abstract 1705: 3D growth modulates the competition between STAT3 and STAT5 in breast cancer
Abstract Approximately 13% of women are diagnosed with invasive breast cancer. Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor t...
Panobinostat Inhibits JAK2/STAT3 Pathway in Multiple Myeloma.
Panobinostat Inhibits JAK2/STAT3 Pathway in Multiple Myeloma.
Abstract Abstract 2849 Poster Board II-825 Histone deacetylase inhibitors (HDACi) are emerging as a potential therapy for Multiple Myel...
Abstract 387: Pyrimethamine inhibits STAT3 transcriptional activity via dihydrofolate reductase
Abstract 387: Pyrimethamine inhibits STAT3 transcriptional activity via dihydrofolate reductase
Abstract Cancer is often characterized by aberrant gene expression patterns that alter cellular function. Such alterations are commonly caused by the inappropriat...

Back to Top